Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Japanese zanidatamab monotherapy trial in advanced HER2-expressing cancers
jRCT2031210161Phase 1Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Aug 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of zanidatamab in HER2-positive cancer (HER2+), gastroesophageal junction adenocarcinoma, biliary cancer and 4 more (2 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Frequency of dose-limiting toxicities, Frequency and severity of adverse events and 7 more. Started Aug 2021; status: completed.
02
Drugs
zanidatamab
03
Conditions
HER2-positive cancer (HER2+)gastroesophageal junction adenocarcinomabiliary cancerbreast cancerovarian cancer
Beyond the preview
Go deeper on jRCT2031210161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210161.